COMPARISON OF REAL-WORLD LATER-LINE TREATMENT OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH (MSI-H) VERSUS MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES (US)

被引：0
|
作者：
Dixon, M. [1 ]
Gu, J. [1 ]
机构：
[1] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO53
引用
收藏
页码：S313 / S314
页数：2
相关论文
共 50 条
  • [41] Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
    Ree, Anne Hansen
    Hamre, Hanne
    Kersten, Christian
    Hofsli, Eva
    Guren, Marianne Gronlie
    Sorbye, Halfdan
    Johansen, Christin
    Negard, Anne
    Flatmark, Kjersti
    Meltzer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
    Ambrosini, M.
    Tougeron, D.
    Modest, P.
    Guimbaud, R.
    Kopetz, S.
    Decraecker, M.
    Sclafani, F.
    Coutzac, C.
    Lievre, A.
    Alouani, E. L.
    Marmorino, F.
    Pernot, S.
    Sinicrope, A.
    Elez Fernandez, E.
    Germani, M. M.
    Pietrantonio, F.
    Lonardi, S.
    Parent, P.
    Gallois, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S32 - S32
  • [43] Development of a cure model for the estimation of long-term outcomes in patients with microsatellite instability(MSI)-high metastatic colorectal cancer (mCRC) receiving immune-checkpoint inhibitors (ICIs)
    Pietrantonio, Filippo
    Infante, Gabriele
    Lonardi, Sara
    Corti, Francesca
    Intini, Rossana
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Belli, Carmen
    Cremolini, Chiara
    Fuca, Giovanni
    Prete, Alessandra Anna
    Quara, Virginia
    Manca, Paolo
    Spallanzani, Andrea
    Morano, Federica
    Di Bartolomeo, Maria
    Curigliano, Giuseppe
    De Braud, Filippo G.
    Zagonel, Vittorina
    Miceli, Rosalba
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [44] Real-world biomarker testing patterns among patients with metastatic colorectal cancer (mCRC) treated with later lines of therapy (LOT) in the United States (US) community oncology setting.
    Katta, Arvind
    Barzi, Afsaneh
    Hocum, Brian Thomas
    Appukkutan, Sreevalsa
    Cosgrove, David
    Sruti, Ila
    Shi, Junxin
    Dai, Wei
    Patton, Gregory A.
    Babajanyan, Svetlana
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 163 - 163
  • [45] Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
    Lenz, H-J. J.
    Van Cutsem, E.
    Limon, M. L.
    Wong, K. Y.
    Hendlisz, A.
    Aglietta, M.
    Garcia-Alfonso, P.
    Neyns, B.
    Luppi, G.
    Cardin, D.
    Dragovich, T.
    Shah, U.
    Atasoy, A.
    Postema, R.
    Boyd, Z.
    Ledeine, J-M.
    Overman, M.
    Lonardi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 714 - 714
  • [46] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [47] Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Bhave, Manali Ajay
    Ntalla, Ioanna
    Lai, Catherine
    Sjekloca, Nikoleta
    Stwalley, Brian
    Stokes, Michael
    Taylor, Aliki
    Nanda, Rita
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 208 (01) : 203 - 214
  • [48] Real-world data on overall survival associated with biweekly versus weekly cetuximab among metastatic colorectal cancer (mCRC) patients in the United States.
    Agg, Himani
    Han, Yimei
    Cui, Zhanglin Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [49] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [50] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Yoshino, T.
    Andre, T.
    Kim, T. W.
    Yong, W. P.
    Shiu, K-K.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez Fernandez, M. E.
    Le, D. T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
12345